Polycythemia Vera (PV) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight 1
DelveInsight Business Research LLP
DelveInsight’s “Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Polycythemia Vera, historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Polycythemia Vera (PV) – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Polycythemia Vera (PV) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Polycythemia Vera (PV), historical and forecasted epidemiology as well as the  Polycythemia Vera (PV) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. According to DelveInsight, the total prevalent population of Polycythemia Vera (PV) in the 7MM was found to be 301,833 in 2017.

  2. Most of the diagnosed prevalence of PV was found in the United States with 107,760 cases in 2017.

  3. Among the European 5 countries, Germany had the highest diagnosed prevalent population of PV with 12,085 cases, followed by Italy and France. On the other hand, Spain had the lowest diagnosed prevalent population of 7,334 in 2017. Japan had 22,974 diagnosed prevalent cases for PV in 2017.

  4. As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for males, in comparison to females, in all the 7MM countries. 

  5. In the total diagnosed prevalent population of PV, patients with JAK2 V617F were assessed to acquire the majority of population share, which equates to ~98% cases experiencing JAK2 gene mutation, in Germany.

Key benefits of the report:

1. Polycythemia Vera (PV) market report covers a descriptive overview and comprehensive insight of the Polycythemia Vera (PV) epidemiology and Polycythemia Vera (PV) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Polycythemia Vera (PV) market report provides insights on the current and emerging therapies.

3. Polycythemia Vera (PV) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Polycythemia Vera (PV) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Polycythemia Vera (PV) market.

Request for sample pages: https://www.delveinsight.com/sample-request/polycythemia-vera-market

Polycythemia Vera (PV): Overview

Polycythemia vera (PV) is a blood cancer that begins in the marrow of your bones, the soft center where new blood cells grow. It causes your marrow to make too many red blood cells so your blood is too thick. You may be more likely to have clots, a stroke, or a heart attack

The key players involved in the Polycythemia Vera (PV) market:

  1. Hoffmann-La Roche 

  2. Kartos Therapeutics 

  3. Italfarmaco  

The launch of the emerging therapies is expected to significantly impact the Polycythemia Vera (PV) treatment scenario in the upcoming years:-

Drug covered

  1. Idasanutlin; RG7388

  2. KRT-232

  3. Givinostat; ITF2357

Request a free sample report @https://www.delveinsight.com/sample-request/polycythemia-vera-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Polycythemia Vera (PV) Patient Share (%) Overview at a Glance

5. Polycythemia Vera (PV) Market Overview at a Glance

6. Polycythemia Vera (PV) Disease Background and Overview

7. Polycythemia Vera (PV) Epidemiology and Patient Population

8. Country-Specific Patient Population of Polycythemia Vera (PV)

9. Polycythemia Vera (PV) Current Treatment and Medical Practices

10. Unmet Needs

11. Polycythemia Vera (PV) Emerging Therapies

12. Polycythemia Vera (PV) Market Outlook

13. Country-Wise Polycythemia Vera (PV) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Polycythemia Vera (PV) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Polycythemia Vera (PV)- Pipeline Insights, 2021

“Polycythemia Vera (PV)- Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Polycythemia Vera (PV) market. A detailed picture of the Polycythemia Vera (PV) pipeline landscape is provided, which includes the disease overview and Polycythemia Vera (PV) treatment guidelines.

Polycythemia Vera (PV) -Epidemiology Forecast to 2030

DelveInsight’s ‘Polycythemia Vera (PV) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Polycythemia Vera (PV) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/